Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Zervimesine (CT1812) in Early Alzheimer's disease. The expected timing is based on the latest available company guidance and may change.
START Trial. 11/02/23- Trial sites activated. 11/13/25- Enrollment completed. Topline results after all participants completed 18mts treatment. 03/02/26:- START Ph2 trial ongoing with $81M grant support; topline results remain after 18-month treatment. 03/26/26:- Completed Dec 2025 enrollment; START Ph2 topline results expected 2027. 05/07/26:- START Phase 2 COG0203 trial in early Alzheimer's disease continues; topline results still anticipated in 2027. 08/06/26:- START Phase 2 study remains ongoing; topline results expected in 2027.
Verification
Confirm timing and program details against the company announcement or filing.